Tangible Shareholders Equity: The value shareholders equity less intangible assets.
Sinovac Biotech, Ltd. (SVA) had Tangible Shareholders Equity of $6.26B for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$10.38B |
|
$858.56M |
|
$1.61B |
|
$11.99B |
|
$5.00B |
|
$233.06M |
|
$642.18M |
|
$5.64B |
|
$6.34B |
|
|
Tangible Shareholders Equity |
$6.26B |
$6.34B |
|
-- |
|
| Cash Flow Statement Financials | |
$-310.65M |
|
$3.99B |
|
$-169.69M |
|
$602.22M |
|
$4.16B |
|
$3.56B |
|
-- |
|
$-234.01M |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|